As a next step, we tested selective BCL-2 protein inhibitors in combination with azacitidine in order to identify the individual contribution of each antiapoptotic BCL-2 protein to the survival of JMML cells. This evidence concerns the gene BCL2 and juvenile myelomonocytic leukemia.